136 related articles for article (PubMed ID: 35961202)
1. A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib.
Malapelle U; Passiglia F
EBioMedicine; 2022 Sep; 83():104213. PubMed ID: 35961202
[No Abstract] [Full Text] [Related]
2. Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization.
Sun Y; Dong Y; Liu X; Zhang Y; Bai H; Duan J; Tian Z; Yan X; Wang J; Wang Z
EBioMedicine; 2022 Sep; 83():104200. PubMed ID: 35932642
[TBL] [Abstract][Full Text] [Related]
3. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract][Full Text] [Related]
4. Acquired Resistance to Osimertinib in
Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940
[TBL] [Abstract][Full Text] [Related]
5. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
[TBL] [Abstract][Full Text] [Related]
6. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.
McCoach CE; Jimeno A
Drugs Today (Barc); 2016 Oct; 52(10):561-568. PubMed ID: 27910964
[TBL] [Abstract][Full Text] [Related]
8. Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid.
Théoleyre S; Masson I; Herbreteau G; Vallée A; Sénellart H; Denis MG
Lung Cancer; 2017 Dec; 114():111-112. PubMed ID: 29096978
[No Abstract] [Full Text] [Related]
9. Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
Wang VE; Gainor JF
JAMA Oncol; 2024 Jan; 10(1):52-53. PubMed ID: 37991771
[No Abstract] [Full Text] [Related]
10. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M
Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257
[TBL] [Abstract][Full Text] [Related]
11. Patients with uncommon EGFR mutations also benefit from first-line osimertinib.
Romero D
Nat Rev Clin Oncol; 2024 Feb; 21(2):84. PubMed ID: 38057403
[No Abstract] [Full Text] [Related]
12. Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC.
Freydman J; Henshaw L; Patel JV; Smith CE; Everett PC
Ann Pharmacother; 2022 Apr; 56(4):503-504. PubMed ID: 34344199
[No Abstract] [Full Text] [Related]
13. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.
Wang S; Tsui ST; Liu C; Song Y; Liu D
J Hematol Oncol; 2016 Jul; 9(1):59. PubMed ID: 27448564
[TBL] [Abstract][Full Text] [Related]
14. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.
Lu K; Woodward BD; Boys J; Onaitis M; Husain H
Clin Lung Cancer; 2024 Jan; 25(1):e58-e61. PubMed ID: 37852849
[No Abstract] [Full Text] [Related]
15. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
Knebel FH; Bettoni F; Shimada AK; Cruz M; Alessi JV; Negrão MV; Reis LFL; Katz A; Camargo AA
Lung Cancer; 2017 Jun; 108():238-241. PubMed ID: 28625643
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib effective in EGFR T790M-positive lung cancer.
Mayor S
Lancet Oncol; 2017 Jan; 18(1):e9. PubMed ID: 27989430
[No Abstract] [Full Text] [Related]
17. Two Driver Mutations Exist in Osimertinib-Resistant Patient Tumors.
Cancer Discov; 2022 Apr; 12(4):OF3. PubMed ID: 35121629
[TBL] [Abstract][Full Text] [Related]
18. Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
Wang Y; Yang N; Zhang Y; Li Li ; Han R; Zhu M; Feng M; Chen H; Lizaso A; Qin T; Liu X; He Y
J Thorac Oncol; 2020 Aug; 15(8):1369-1375. PubMed ID: 32353596
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review.
Nargesi S; Dolatshahi Z; Rezapour A; Alipour V; Souresrafil A; Farabi H; Javadmoosavi SA; Safakhah M; Moradi N
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):543-554. PubMed ID: 34846235
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.
Gao X; Le X; Costa DB
Expert Rev Anticancer Ther; 2016; 16(4):383-90. PubMed ID: 26943236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]